Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine and Standard Of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma

NCT04627246 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire Vaudois as lead sponsor.

NCT NCT04627246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04627246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine and Standard Of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma
Lead sponsor
Centre Hospitalier Universitaire Vaudois
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 11, 2020
Completion date
September 30, 2028
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma